- Home
- SYRS vs NLSP Comparison
SYRS vs NLSP Comparison
Compare SYRS & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRS
- NLSP
- Stock Information
- Founded
- SYRS 2011
- NLSP 2015
- Country
- SYRS United States
- NLSP Switzerland
- Employees
- SYRS N/A
- NLSP N/A
- Industry
- SYRS Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- SYRS Health Care
- NLSP Health Care
- Exchange
- SYRS Nasdaq
- NLSP Nasdaq
- Market Cap
- SYRS 5.7M
- NLSP 6.2M
- IPO Year
- SYRS 2016
- NLSP 2021
- Fundamental
- Price
- SYRS $0.17
- NLSP $1.95
- Analyst Decision
- SYRS Hold
- NLSP
- Analyst Count
- SYRS 5
- NLSP 0
- Target Price
- SYRS $3.00
- NLSP N/A
- AVG Volume (30 Days)
- SYRS 1.2M
- NLSP 6.1M
- Earning Date
- SYRS 03-26-2025
- NLSP 10-18-2024
- Dividend Yield
- SYRS N/A
- NLSP N/A
- EPS Growth
- SYRS N/A
- NLSP N/A
- EPS
- SYRS N/A
- NLSP N/A
- Revenue
- SYRS $386,000.00
- NLSP N/A
- Revenue This Year
- SYRS N/A
- NLSP N/A
- Revenue Next Year
- SYRS N/A
- NLSP N/A
- P/E Ratio
- SYRS N/A
- NLSP N/A
- Revenue Growth
- SYRS N/A
- NLSP N/A
- 52 Week Low
- SYRS $0.16
- NLSP $1.71
- 52 Week High
- SYRS $7.96
- NLSP $18.40
- Technical
- Relative Strength Index (RSI)
- SYRS 38.78
- NLSP 44.06
- Support Level
- SYRS $0.16
- NLSP $2.14
- Resistance Level
- SYRS $0.20
- NLSP $2.34
- Average True Range (ATR)
- SYRS 0.02
- NLSP 0.24
- MACD
- SYRS 0.01
- NLSP -0.00
- Stochastic Oscillator
- SYRS 35.75
- NLSP 12.07
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.